A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it
is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what
its side effects are. A side effect is anything the drug does besides treating cancer. It
will also study whether SEA-TGT works to treat solid tumors and lymphomas.
The study will have three parts. Part A of the study will find out how much SEA-TGT should be
given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is
and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with
sasanlimab works to treat solid tumors.